Ranbaxy In-licenses Cosmetic Product For Indian Market

Ranbaxy has entered into a strategic in-licensing agreement for the Indian market, with Medy-Tox, South Korea’s Botulinum -Toxin specialised Biotech Venture, for its cosmetic product, Neuronox. The introduction of the new alternative brand of Purified Botulinum Toxin Type -A, is said to strengthen the company’s presence in the Dermatological segment.

Therapeutic equivalence and clinical trials conducted by Medy-Tox, have confirmed the efficacy and safety of Neuronox in all respects. This product is now made available in India through Ranbaxy.

Sanjeev Dani, SVP and regional director of Asia & CIS at Ranbaxy, said: “Neuronox comes as a welcome alternative to Dermatologists in India and we aim to make Botulinum Toxin therapy more accessible and affordable to people in the country.”

Botulinum Toxin Type -A, an anti-ageing medicine, is used in the correction of facial wrinkles and hyperhidrosis.